Stockscreener 앱 받기
268.80
0.57%
1.52
시장 영업 전:
278.00
9.20
+3.42%
전일 마감가:
$267.28
열려 있는:
$263.98
하루 거래량:
402.80K
Relative Volume:
0.41
시가총액:
$6.72B
수익:
$1.77M
순이익/손실:
$-123.74M
주가수익비율:
-29.31
EPS:
-9.17
순현금흐름:
$-95.21M
1주 성능:
+8.39%
1개월 성능:
+46.40%
6개월 성능:
+496.94%
1년 성능:
+278.59%
1일 변동 폭
$263.84
$274.35
1주일 범위
$251.00
$278.44
52주 변동 폭
$26.70
$278.44
Praxis Precision Medicines Inc Stock (PRAX) Company Profile
명칭
Praxis Precision Medicines Inc
전화
617-300-8460
주소
99 HIGH STREET, 30TH FLOOR, BOSTON
PRAX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PRAX
Praxis Precision Medicines Inc
|
268.80 | 6.68B | 1.77M | -123.74M | -95.21M | -9.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-19 | 개시 | BTIG Research | Buy |
| 2025-06-02 | 재개 | Oppenheimer | Outperform |
| 2025-05-07 | 개시 | Chardan Capital Markets | Buy |
| 2025-03-03 | 재확인 | H.C. Wainwright | Buy |
| 2025-02-11 | 개시 | Deutsche Bank | Buy |
| 2024-08-05 | 개시 | Oppenheimer | Outperform |
| 2024-06-24 | 개시 | Needham | Buy |
| 2024-06-18 | 개시 | Guggenheim | Buy |
| 2024-05-01 | 개시 | Robert W. Baird | Outperform |
| 2023-09-19 | 개시 | Truist | Buy |
| 2022-06-06 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2021-12-16 | 개시 | H.C. Wainwright | Buy |
| 2021-08-26 | 개시 | BofA Securities | Buy |
| 2021-04-26 | 개시 | William Blair | Outperform |
| 2020-11-11 | 개시 | Wedbush | Outperform |
| 2020-11-10 | 개시 | Cowen | Outperform |
| 2020-11-10 | 개시 | Evercore ISI | Outperform |
| 2020-11-10 | 개시 | Piper Sandler | Overweight |
모두보기
Praxis Precision Medicines Inc 주식(PRAX)의 최신 뉴스
Praxis Precision Medicines stock price target raised to $750 from $250 at Oppenheimer - Investing.com UK
Best Pharmaceutical Stocks To Watch TodayDecember 5th - MarketBeat
(PRAX) Price Dynamics and Execution-Aware Positioning - news.stocktradersdaily.com
Praxis Precision Medicines Plans New Drug Application - The Globe and Mail
Praxis Precision to file an NDA for relutrigine in encephalopathies in 2026 - Yahoo Finance
Deutsche Bank Raises Price Target on Praxis Precision Medicines to $313 From $303, Keeps Buy Rating - marketscreener.com
OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Reduces Stock Position in Praxis Precision Medicines, Inc. $PRAX - MarketBeat
Praxis tees up another approval filing; Geron turns to layoffs - Yahoo Finance
Praxis Precision Medicines updates clinical trial design and regulatory plans - Investing.com
Praxis, FDA agree on pivotal trial changes for encephalopathy asset elsunersen - MSN
Praxis Precision Medicines Confirms FDA Filing Path for New Drug Application of Relutrigine in Early 2026 - Quiver Quantitative
TD Cowen lifts Praxis Precision Medicines Inc. (PRAX) price target amid NDA for essential tremor treatment - MSN
Praxis Precision Medicines Announces Plans to File an NDA - GlobeNewswire
TD Cowen Lifts Praxis Precision Medicines Inc. (PRAX) Price Target amid NDA for Essential Tremor Treatment - Insider Monkey
HighVista Strategies LLC Buys 28,002 Shares of Praxis Precision Medicines, Inc. $PRAX - MarketBeat
Praxis a new buy at BTIG as biotech is a top pick for 2026 - MSN
Stempoint Capital LP Takes $1.36 Million Position in Praxis Precision Medicines, Inc. $PRAX - MarketBeat
Maven Securities LTD Buys Shares of 5,000 Praxis Precision Medicines, Inc. $PRAX - MarketBeat
PRAX Adjusts EMBRAVE3 Study Design After FDA Meeting - GuruFocus
Praxis Precision Medicines Announces FDA Approval for EMBRAVE3 Trial Design Change for Elsunersen in SCN2A Developmental and Epileptic Encephalopathy - Quiver Quantitative
Praxis Precision Medicines announces alignment with FDA - marketscreener.com
PRAX Stock Research: Jefferies Raises Price Target by 50% on Dec - GuruFocus
Praxis Precision (NASDAQ: PRAX) gets FDA nod for single-arm Elsunersen EMBRAVE3 trial - Stock Titan
Guggenheim Maintains Praxis Precision Medicines (PRAX) Buy Recommendation - Nasdaq
PRAX Stock Skyrockets 520% in 3 Months: Here's What You Need to Know - Eastern Progress
Praxis Precision Medicines (PRAX) Soars on FDA Momentum and 760-Dollar Target: December 9, 2025 Stock Deep Dive - ts2.tech
Vivo Capital LLC Takes Position in Praxis Precision Medicines, Inc. $PRAX - MarketBeat
Praxis Precision Medicines, Inc. $PRAX Shares Bought by Swiss National Bank - MarketBeat
Praxis Precision Medicine (PRAX): Guggenheim Raises Price Target to $760 | PRAX Stock News - GuruFocus
Praxis Precision Medicines Inc. (PRAX) secures analyst confidence after key FDA and trial wins - MSN
Needham raises Praxis Precision Medicines stock price target on improved data - Investing.com Australia
Praxis Precision Medicines, Inc. $PRAX Stock Holdings Boosted by B Group Inc. - MarketBeat
Praxis Precision Medicines Inc. (PRAX) Secures Analyst Confidence After Key FDA and Trial Wins - Insider Monkey
BTIG maintains Praxis Precision Medicines (PRAX) buy recommendation - MSN
PRAX Stock Surge: Rally or Risk? - StocksToTrade
Praxis Precision Medicines reports clinical updates on epilepsy drug candidates - Investing.com Nigeria
Praxis Precision Medicines Shares RADIANT Study Results - TipRanks
TD Cowen Maintains Praxis Precision Medicines (PRAX) Buy Recommendation - Nasdaq
Praxis Precision Medicines (NASDAQ:PRAX) Price Target Raised to $353.00 - MarketBeat
TD Cowen Raises Price Target for PRAX to $353, Maintains Buy Rat - GuruFocus
Praxis Precision Medicines stock price target raised to $353 from $251 at TD Cowen - Investing.com Nigeria
Truist Securities Raises Price Target for PRAX to $500 | PRAX St - GuruFocus
Praxis Precision Medicines (NASDAQ:PRAX) Given New $500.00 Price Target at Truist Financial - MarketBeat
Praxis Precision Medicines (NASDAQ:PRAX) Stock Price Up 9.2% Following Analyst Upgrade - MarketBeat
Truist Securities raises Praxis Precision Medicines stock price target to $500 - Investing.com Nigeria
Guggenheim raises Praxis Precision Medicines stock price target to $760 on strong epilepsy data By Investing.com - Investing.com South Africa
PRAX Releases Promising Clinical Updates on Epilepsy Treatments - GuruFocus
Praxis Precision Medicine (PRAX) Sees Raised Price Target by Nee - GuruFocus
Needham & Company LLC Forecasts Strong Price Appreciation for Praxis Precision Medicines (NASDAQ:PRAX) Stock - MarketBeat
Praxis Precision Medicines Reports Positive EMBOLD and RADIANT Study Results for Relutrigine and Vormatrigine in Epilepsy Treatment - Quiver Quantitative
Praxis AES Wrap-up: Best-in-Class Potential Across Rare Pediatric and Adult Epilepsies - The Manila Times
Praxis Precision Medicines Inc (PRAX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Praxis Precision Medicines Inc 주식 (PRAX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Nemiroff Alex | General Counsel and Secretary |
Nov 20 '25 |
Sale |
193.09 |
25,130 |
4,852,256 |
20,832 |
| Mastrocola Lauren | Principal Accounting Officer |
Nov 20 '25 |
Option Exercise |
61.12 |
13,600 |
831,257 |
24,042 |
| Mastrocola Lauren | Principal Accounting Officer |
Nov 20 '25 |
Sale |
192.08 |
13,600 |
2,612,244 |
10,442 |
1.08%
0.91%
자본화:
|
볼륨(24시간):